Drugs / BEROTERKIB ANHYDROUS

Trials 3 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT04466514 Jul → Oct 2020 Astex Pharmaceuticals, Inc. Completed No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT06284460 Jan → Dec 2025 myelodysplastic syndrome, myeloproliferative neoplasm M.D. Anderson Cancer Center Withdrawn No outcome recorded
Phase 1/2 NCT03520075 May 2018 → Aug 2024 cancer Taiho Oncology, Inc. Completed No outcome recorded

Evidence & citations 10 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as BEROTERKIB ANHYDROUS ChEMBL registry synonym — accepted as the source's own label CHEMBL4847260
Known as ASTX-029 MONOHYDRATE ChEMBL registry synonym — accepted as the source's own label CHEMBL4847260
Known as ASTX029 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03520075
2

NCT06284460

NCT04466514

Known as AT-35029 ChEMBL registry synonym — accepted as the source's own label CHEMBL4847260
Known as AT-35029 MONOHYDRATE ChEMBL registry synonym — accepted as the source's own label CHEMBL4847260
Known as BEROTERKIB ChEMBL registry synonym — accepted as the source's own label CHEMBL4847260
Known as Beroterkib monohydrate ChEMBL registry synonym — accepted as the source's own label CHEMBL4847260
Action Inhibit “ASTX029 is a synthetic small molecule inhibitor of extracellular signal-regulated kinases (ERKs) 1/2.” NCT03520075
Modality Small molecule “ASTX029 is a synthetic small molecule inhibitor of extracellular signal-regulated kinases (ERKs) 1/2.” NCT03520075
Route Oral “ASTX029 administered orally” NCT03520075